On 27 march, the zhejiang province of zhejiang held a conference on the management of cosmetics for medical equipment in the city. It was suggested that a breakthrough in regulatory reform could drive industrial development by enabling innovation, enabling access to the sea and enabling transformation in the evolution of the matrix industry。
Innovation breaker: from "run" to "lead"
In order to break down the biomedicine industry pattern in zhejiang province, which is characterized by a “less-armed and less chemical” industry, and to accelerate the transition from a “simulation and running” to an “innovation lead”, the zhejiang provincial drug monitoring authority (hereinafter referred to as the zhejiang provincial drug regulatory authority) is working to break down institutional barriers to innovation incentives and review approvals through deeper and more accurate drug regulatory reform。
At the meeting, wang jiu, director-general of the zhejiang provincial drug inspectorate, stated that during the “fifty-five” period, additional efforts would be made to advance the “seven visions” development mission, which proposed, inter alia, deepening innovative service platforms and regional development strategy escort actions to enhance the innovative resources and core competitiveness of the pharmaceutical industry。
The province will also continue to implement the scale-up of drug testing and testing capabilities, as well as a dedicated capacity-building programme for medical devices, to provide standard leadership for innovative actions to support product development and innovation. In frontier tracks such as artificial intelligence (ai) pharmaceuticals, the acceleration pushes results to the ground。
Zhejiang province, 2026, on the site of a conference on the supervision and management of cosmetics for pharmaceutical medical devices. Pan xinwen
Open power: building bridges for new medicines
In the context of globalization, support for innovative drug research and development and access to the sea has become a major driving force for the development of the pharmaceutical industry。
The zhejiang provincial drug authority will intensify its communication with the national drug authority and actively seek policy support to enable the province's reform services to be “quick” in order to increase the number of innovative products entering breakthrough therapy, conditional approval, priority review and clearance。
During the “fifty-five” period, the province will strengthen its cooperation and exchange with the outside world through open cooperation enabling actions to develop a modern system of drug regulation with international reach, national leadership and characteristics of the zhejiang。
Forward-looking layout: taking over a new future industry track
With the development of cutting-edge technologies such as artificial intelligence (ai), quantum science and biotechnology, industrial development in the field of drug weaponization in zhejiang province has also ushered in a window period for overcargoing。
“to enhance the sense of urgency of pre-emption, forward-disturbing nuclear medicines, brain interfaces, bio-manufacturing, and other future industries, support original and subversive innovations guided by clinical demand, and secure the initiative to develop the productivity of new medicines.” the royal motivation。
The zhejiang are investing in new growth points in the biopharmaceutical industry, ranging from new areas such as the growth of synthetic organisms, zero-magnetic medicine and surgical robots, to the development of marine pharmaceuticals and radioactive drugs。
While regulation goes beyond “managing risks”, it also has to be balanced with “managing dynamism”, and zhejiang is setting clear “roadmarks” for industry with “three powers” — innovation driven by regulatory reforms, support by policy, and pre-positioning to take control of the course and inject new dynamics into the quality development of the pharmaceutical industry. (concluded)
